Radiotheranostics, injectable radiopharmaceuticals with antitumour effects, have seen rapid
development over the past decade. Although some formulations are already approved for …

OBJECTIVE. Several clinical studies have shown the efficacy of 177Lu-labeled prostate-
specific membrane antigen (PSMA) radioligand therapy (RLT) for metastatic castration …

Prostate-specific membrane antigen (PSMA) is expressed in most prostate cancers and can
be identified by PSMA-ligand imaging, which has already become clinically accepted in …

Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically
significant prostate adenocarcinomas, and patients with target-positive disease can easily …

Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is
increasingly being used in metastatic castration-resistant prostate cancer (mCRPC). The …

Rationale: Despite the success of several standards of care treatment options in metastatic
castration-resistant prostate cancer (mCRPC), a significant number of patients attain …

Prostate-specific membrane antigen (PSMA) is a promising target for imaging diagnostics
and targeted radionuclide therapy (theranostics) of prostate cancer and its metastases …

The introduction of second-generation androgen receptor antagonists (SG-ARAs) has
greatly impacted the treatment of metastatic prostate cancer, providing tolerable and …

Aims There is a controversy as to the relative efficacy of 177 Lu prostate specific membrane
antigen (PSMA) radioligand therapy (RLT) and third-line treatment for patients with …

Background Prostate-specific membrane antigen (PSMA) is overexpressed in metastatic
castration-resistant prostate cancer (mCRPC) and represents a target for imaging and …